Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life

OBJECTIVE: The aim of this study was to determine if direct-acting antiviral (DAA) treatment with daclatasvir (DCV) plus asunaprevir (ASV) for 24 weeks influenced the health-related quality of life (HRQOL) at 12 and 24 weeks after treatment initiation [end of treatment (EOT)]. METHODS: This was a pr...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Intern Med
Glavni autori: Kawakubo, Megumi, Eguchi, Yuichiro, Okada, Michiaki, Iwane, Shinji, Oeda, Satoshi, Otsuka, Taiga, Nakashita, Syunya, Araki, Norimasa, Koga, Akemi
Format: Artigo
Jezik:Inglês
Izdano: The Japanese Society of Internal Medicine 2018
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6096027/
https://ncbi.nlm.nih.gov/pubmed/29526929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.0091-17
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items